NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Cancer (UK). Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients. London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
Show detailsDefinition of neutropenia and fever
- Diagnose neutropenic sepsis in patients having anticancer treatment whose neutrophil count is 0.5 × 109 per litre or lower and who have either:
Information and support for patients and carers
- Provide patients having anticancer treatment and their carers with written and oral information, both before starting and throughout their anticancer treatment, on:
- -
- -
how and when to contact 24-hour specialist oncology advice
- -
how and when to seek emergency care.
Investigations appropriate for clinical management and risk stratification
- Include in the initial clinical assessment of patients with suspected neutropenic sepsis:
- -
history and examination
- -
full blood count, kidney and liver function tests (including albumin), C-reactive protein, lactate and blood culture (see also recommendations in section 4.2.2).
Assessing the patient's risk of septic complications
- A healthcare professional with competence in managing complications of anticancer treatment should assess the patient's risk of septic complications within 24 hours of presentation to secondary or tertiary care, basing the risk assessment on presentation features and using a validated risk scoring system1.
Reducing the risk of septic complications of anticancer treatment
- For adult patients (aged 18 years and older) with acute leukaemias, stem cell transplants or solid tumours in whom significant neutropenia (neutrophil count 0.5 × 109 per litre or lower) is an anticipated consequence of chemotherapy, offer prophylaxis with a fluoroquinolone during the expected period of neutropenia only.
Timing of initial antibiotic treatment
- Treat suspected neutropenic sepsis as an acute medical emergency and offer empiric antibiotic therapy immediately.
Empiric intravenous antibiotic monotherapy or intravenous antibiotic dual therapy
- Offer beta lactam monotherapy with piperacillin with tazobactam2 as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment unless there are patient-specific or local microbiological contraindications.
- Do not offer an aminoglycoside, either as monotherapy or in dual therapy, for the initial empiric treatment of suspected neutropenic sepsis unless there are patient-specific or local microbiological indications.
Inpatient versus outpatient management strategies
- Consider outpatient antibiotic therapy for patients with confirmed neutropenic sepsis and a low risk of developing septic complications, taking into account the patient's social and clinical circumstances and discussing with them the need to return to hospital promptly if a problem develops.
Duration of inpatient care
- Offer discharge to patients having empiric antibiotic therapy for neutropenic sepsis only after:
- -
the patient's risk of developing septic complications has been reassessed as low by a healthcare professional with competence in managing complications of anticancer treatment using a validated risk scoring system3 and
- -
taking into account the patient's social and clinical circumstances and discussing with them the need to return to hospital promptly if a problem develops.
Footnotes
- 1
Examples of risk scoring systems include The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology. 2000;18:3038–51. [PubMed: 10944139] and the modified Alexander rule for children (aged under 18). European Journal of Cancer. 2009;45:2843–9. [PubMed: 19616427].
- 2
At the time of publication (September 2012) piperacillin with tazobactam did not have a UK marketing authorisation for use in children aged under 2 years. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. The child's parent or carer should provide informed consent, which should be documented. See the GMC's Good practice in prescribing medicines – guidance for doctors and the prescribing advice provided by the Joint Standing Committee on Medicines (a joint committee of the Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group) for further information.
- 3
Examples of risk scoring systems include The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology. 2000;18:3038–51. [PubMed: 10944139] and the modified Alexander rule for children (aged under 18). European Journal of Cancer. 2009;45:2843–9. [PubMed: 19616427].
- Definition of neutropenia and fever
- Information and support for patients and carers
- Investigations appropriate for clinical management and risk stratification
- Assessing the patient's risk of septic complications
- Reducing the risk of septic complications of anticancer treatment
- Timing of initial antibiotic treatment
- Empiric intravenous antibiotic monotherapy or intravenous antibiotic dual therapy
- Inpatient versus outpatient management strategies
- Duration of inpatient care
- Key priorities for implementation - Neutropenic Sepsis: Prevention and Managemen...Key priorities for implementation - Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Your browsing activity is empty.
Activity recording is turned off.
See more...